Public product phase now, structured medical research later

Current phase

Right now, the product direction is intentionally conservative. We want to validate the core mechanism with low-risk categories before attempting anything more ambitious. That means testing how users respond to open-label placebo routines, cue delivery, structured logging, and recommendation loops in scenarios where safety boundaries are easier to define.

This public phase should help answer practical questions: whether people engage consistently, whether cues can shape subjective outcomes, whether override behavior is informative, and whether the system can produce useful behavioral data without relying on deception.

What we want to learn

• How expectation and ritual interact with safe, repeat-use products.
• Which cue formats produce the strongest and most reliable learned response.
• How much individual adaptation matters for real-world effectiveness.
• When users choose to override placebo recommendations and why.
• What evidence is needed before progressing into formal clinical collaboration.

Long-term research direction

The end goal is larger than a wellness app. If the public phase shows meaningful and repeatable effects, Placebo-Life should become the basis for real medical research aimed at reducing usage, dependency, or side effects associated with stronger substances and treatments.

That future work would require clinical governance, ethics review, and carefully designed study protocols. The ambition is to explore whether transparent conditioning models could support lower exposure to real drugs in some contexts, including substances such as oxytocin, while preserving safety and scientific credibility.

Research principles

• Transparency before persuasion.
• User control before automation.
• Safe product validation before medical escalation.
• Evidence generation before therapeutic claims.
• Clinical partnerships before any real-drug protocol.